Note to users. If you're seeing this message, it means that your browser cannot find this page's style/presentation instructions -- or possibly that you are using a browser that does not support current Web standards. Find out more about why this message is appearing, and what you can do to make your experience of our site the best it can be.

Science 11 July 1986:
Vol. 233. no. 4760, pp. 212 - 214
DOI: 10.1126/science.3460176
Prev | Table of Contents | Next

Articles

Science, Vol 233, Issue 4760, 212-214
Copyright © 1986 by American Association for the Advancement of Science

articles

The chronic myelogenous leukemia-specific P210 protein is the product of the bcr/abl hybrid gene

Y Ben-Neriah, GQ Daley, AM Mes-Masson, ON Witte, and D Baltimore

Chronic myelogenous leukemia (CML) is a human disease associated with a consistent chromosomal translocation that results in sequences from the c-abl locus on chromosome 9 being fused to sequences in a breakpoint cluster region (bcr) on chromosome 22. CML cells have two novel products: an 8.5-kilobase RNA transcript containing both abl and bcr and a 210-kilodalton phosphoprotein (P210) recognized by v-abl-specific antisera. To test whether the P210 is the product of the novel 8.5-kilobase bcr/abl fusion transcript, antibodies were prepared against c-abl and bcr determinants. By using these reagents and v-abl-specific antisera, it was demonstrated that the P210 in CML cells is indeed the protein product of the 8.5-kilobase transcript. By analogy to the gag/abl fusion protein of Abelson murine leukemia virus, the replacement of amino terminal c-abl sequences by bcr sequences in P210 may create a transforming protein involved in CML. A 190-kilodalton phosphoprotein that is a candidate for the normal bcr protein was identified in both HeLa and K562 cells.


THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES:
Chronic myeloid leukemia patients with the e13a2 BCR-ABL fusion transcript have inferior responses to imatinib compared to patients with the e14a2 transcript.
C. M. Lucas, R. J. Harris, A. Giannoudis, A. Davies, K. Knight, S. J. Watmough, L. Wang, and R. E. Clark (2009)
Haematologica 94, 1362-1367
   Abstract »    Full Text »    PDF »
c-Abl-deficient mice exhibit reduced numbers of peritoneal B-1 cells and defects in BCR-induced B cell activation.
R. A. Liberatore and S. P. Goff (2009)
Int. Immunol. 21, 403-414
   Abstract »    Full Text »    PDF »
Translation of the Philadelphia chromosome into therapy for CML.
B. J. Druker (2008)
Blood 112, 4808-4817
   Abstract »    Full Text »    PDF »
Requirement of c-Myb for p210BCR/ABL-dependent transformation of hematopoietic progenitors and leukemogenesis.
M. R. Lidonnici, F. Corradini, T. Waldron, T. P. Bender, and B. Calabretta (2008)
Blood 111, 4771-4779
   Abstract »    Full Text »    PDF »
Suppression of Interferon (IFN)-inducible Genes and IFN-mediated Functional Responses in BCR-ABL-expressing Cells.
E. Katsoulidis, A. Sassano, B. Majchrzak-Kita, N. Carayol, P. Yoon, A. Jordan, B. J. Druker, E. N. Fish, and L. C. Platanias (2008)
J. Biol. Chem. 283, 10793-10803
   Abstract »    Full Text »    PDF »
Suppression of Programmed Cell Death 4 (PDCD4) Protein Expression by BCR-ABL-regulated Engagement of the mTOR/p70 S6 Kinase Pathway.
N. Carayol, E. Katsoulidis, A. Sassano, J. K. Altman, B. J. Druker, and L. C. Platanias (2008)
J. Biol. Chem. 283, 8601-8610
   Abstract »    Full Text »    PDF »
Age-related defects in B lymphopoiesis underlie the myeloid dominance of adult leukemia.
R. A. J. Signer, E. Montecino-Rodriguez, O. N. Witte, J. McLaughlin, and K. Dorshkind (2007)
Blood 110, 1831-1839
   Abstract »    Full Text »    PDF »
Activation of a novel Bcr/Abl destruction pathway by WP1130 induces apoptosis of chronic myelogenous leukemia cells.
G. A. Bartholomeusz, M. Talpaz, V. Kapuria, L. Y. Kong, S. Wang, Z. Estrov, W. Priebe, J. Wu, and N. J. Donato (2007)
Blood 109, 3470-3478
   Abstract »    Full Text »    PDF »
SHP-2 phosphatase is required for hematopoietic cell transformation by Bcr-Abl.
J. Chen, W.-M. Yu, H. Daino, H. E. Broxmeyer, B. J. Druker, and C.-K. Qu (2007)
Blood 109, 778-785
   Abstract »    Full Text »    PDF »
Activation of mammalian target of rapamycin and the p70 S6 kinase by arsenic trioxide in BCR-ABL-expressing cells..
P. Yoon, N. Giafis, J. Smith, H. Mears, E. Katsoulidis, A. Sassano, J. Altman, A. J. Redig, M. S. Tallman, and L. C. Platanias (2006)
Mol. Cancer Ther. 5, 2815-2823
   Abstract »    Full Text »    PDF »
Leukemogenesis induced by wild-type and STI571-resistant BCR/ABL is potently suppressed by C/EBP{alpha}.
G. Ferrari-Amorotti, K. Keeshan, M. Zattoni, C. Guerzoni, G. Iotti, S. Cattelani, N. J. Donato, and B. Calabretta (2006)
Blood 108, 1353-1362
   Abstract »    Full Text »    PDF »
BCR-ABL Is Not an Immunodominant Antigen in Chronic Myelogenous Leukemia.
F. Grunebach, V. Mirakaj, V. Mirakaj, M. R. Muller, T. Brummendorf, and P. Brossart (2006)
Cancer Res. 66, 5892-5900
   Abstract »    Full Text »    PDF »
Inducible activation of CEBPB, a gene negatively regulated by BCR/ABL, inhibits proliferation and promotes differentiation of BCR/ABL-expressing cells.
C. Guerzoni, M. Bardini, S. A. Mariani, G. Ferrari-Amorotti, P. Neviani, M. L. Panno, Y. Zhang, R. Martinez, D. Perrotti, and B. Calabretta (2006)
Blood 107, 4080-4089
   Abstract »    Full Text »    PDF »
Differential regulation of the p70 S6 kinase pathway by interferon {alpha} (IFN{alpha}) and imatinib mesylate (STI571) in chronic myelogenous leukemia cells.
S. Parmar, J. Smith, A. Sassano, S. Uddin, E. Katsoulidis, B. Majchrzak, S. Kambhampati, E. A. Eklund, M. S. Tallman, E. N. Fish, et al. (2005)
Blood 106, 2436-2443
   Abstract »    Full Text »    PDF »
Introduction to a Cancer Symposium for the Practitioner.
A. Tefferi, S. V. Rajkumar, and A. A. Adjei (2005)
Mayo Clin. Proc. 80, 1085-1086
   PDF »
Chronic Myeloid Leukemia: Current Application of Cytogenetics and Molecular Testing for Diagnosis and Treatment.
A. Tefferi, G. W. Dewald, M. L. Litzow, J. Cortes, M. J. Mauro, M. Talpaz, and H. M. Kantarjian (2005)
Mayo Clin. Proc. 80, 390-402
   Abstract »    PDF »
Global Effects of BCR/ABL and TEL/PDGFR{beta} Expression on the Proteome and Phosphoproteome: IDENTIFICATION OF THE RHO PATHWAY AS A TARGET OF BCR/ABL.
R. D. Unwin, D. W. Sternberg, Y. Lu, A. Pierce, D. G. Gilliland, and A. D. Whetton (2005)
J. Biol. Chem. 280, 6316-6326
   Abstract »    Full Text »    PDF »
Imatinib mesylate inhibits T-cell proliferation in vitro and delayed-type hypersensitivity in vivo.
A. B. Dietz, L. Souan, G. J. Knutson, P. A. Bulur, M. R. Litzow, and S. Vuk-Pavlovic (2004)
Blood 104, 1094-1099
   Abstract »    Full Text »    PDF »
Granulocyte-Macrophage Progenitors as Candidate Leukemic Stem Cells in Blast-Crisis CML.
C. H.M. Jamieson, L. E. Ailles, S. J. Dylla, M. Muijtjens, C. Jones, J. L. Zehnder, J. Gotlib, K. Li, M. G. Manz, A. Keating, et al. (2004)
N. Engl. J. Med. 351, 657-667
   Abstract »    Full Text »    PDF »
Role of the p38 Mitogen-activated Protein Kinase Pathway in the Generation of the Effects of Imatinib Mesylate (STI571) in BCR-ABL-expressing Cells.
S. Parmar, E. Katsoulidis, A. Verma, Y. Li, A. Sassano, L. Lal, B. Majchrzak, F. Ravandi, M. S. Tallman, E. N. Fish, et al. (2004)
J. Biol. Chem. 279, 25345-25352
   Abstract »    Full Text »    PDF »
The biology of CML blast crisis.
B. Calabretta and D. Perrotti (2004)
Blood 103, 4010-4022
   Abstract »    Full Text »    PDF »
Cancer Stem Cells: Are We Missing the Target?.
R. J. Jones, W. H. Matsui, and B. D. Smith (2004)
J Natl Cancer Inst 96, 583-585
   Full Text »    PDF »
A multivalent bcr-abl fusion peptide vaccination trial in patients with chronic myeloid leukemia.
K. Cathcart, J. Pinilla-Ibarz, T. Korontsvit, J. Schwartz, V. Zakhaleva, E. B. Papadopoulos, and D. A. Scheinberg (2004)
Blood 103, 1037-1042
   Abstract »    Full Text »    PDF »
Imatinib As a Paradigm of Targeted Therapies.
B. J. Druker (2003)
J. Clin. Oncol. 21, 239s-245
   Full Text »    PDF »
Cell context-specific effects of the BCR-ABL oncogene monitored in hematopoietic progenitors.
S. Wong, J. McLaughlin, D. Cheng, and O. N. Witte (2003)
Blood 101, 4088-4097
   Abstract »    Full Text »    PDF »
The Effect of Imatinib Mesylate on Patients with Philadelphia Chromosome-positive Chronic Myeloid Leukemia with Secondary Chromosomal Aberrations.
A. N. Mohamed, P. Pemberton, J. Zonder, and C. A. Schiffer (2003)
Clin. Cancer Res. 9, 1333-1337
   Abstract »    Full Text »    PDF »
BCR/ABL-mediated Increased Expression of Multiple Known and Novel Genes That May Contribute to the Pathogenesis of Chronic Myelogenous Leukemia.
S. Salesse and C. M. Verfaillie (2003)
Mol. Cancer Ther. 2, 173-182
   Abstract »    Full Text »    PDF »
Polycythemia Vera: A Comprehensive Review and Clinical Recommendations.
A. Tefferi (2003)
Mayo Clin. Proc. 78, 174-194
   Abstract »    PDF »
Activation of Rac1 and the p38 Mitogen-activated Protein Kinase Pathway in Response to Arsenic Trioxide.
A. Verma, M. Mohindru, D. K. Deb, A. Sassano, S. Kambhampati, F. Ravandi, S. Minucci, D. V. Kalvakolanu, and L. C. Platanias (2002)
J. Biol. Chem. 277, 44988-44995
   Abstract »    Full Text »    PDF »
BCR/ABL induces expression of vascular endothelial growth factor and its transcriptional activator, hypoxia inducible factor-1alpha , through a pathway involving phosphoinositide 3-kinase and the mammalian target of rapamycin.
M. Mayerhofer, P. Valent, W. R. Sperr, J. D. Griffin, and C. Sillaber (2002)
Blood 100, 3767-3775
   Abstract »    Full Text »    PDF »
A phase 2 study of imatinib in patients with relapsed or refractory Philadelphia chromosome-positive acute lymphoid leukemias.
O. G. Ottmann, B. J. Druker, C. L. Sawyers, J. M. Goldman, J. Reiffers, R. T. Silver, S. Tura, T. Fischer, M. W. Deininger, C. A. Schiffer, et al. (2002)
Blood 100, 1965-1971
   Abstract »    Full Text »    PDF »
Modulation of p210BCR-ABL activity in transduced primary human hematopoietic cells controls lineage programming.
Y. Chalandon, X. Jiang, G. Hazlewood, S. Loutet, E. Conneally, A. Eaves, and C. Eaves (2002)
Blood 99, 3197-3204
   Abstract »    Full Text »    PDF »
Leading prognostic relevance of the BCR-ABL translocation in adult acute B-lineage lymphoblastic leukemia: a prospective study of the German Multicenter Trial Group and confirmed polymerase chain reaction analysis.
B. Glei{beta}ner, N. Gokbuget, C. R. Bartram, B. Janssen, H. Rieder, J. W. G. Janssen, C. Fonatsch, A. Heyll, D. Voliotis, J. Beck, et al. (2002)
Blood 99, 1536-1543
   Abstract »    Full Text »    PDF »
STI571: A Paradigm of New Agents for Cancer Therapeutics.
M. J. Mauro, M. O'Dwyer, M. C. Heinrich, and B. J. Druker (2002)
J. Clin. Oncol. 20, 325-334
   Abstract »    Full Text »    PDF »
Pharmacologic Mitogen-activated Protein/Extracellular Signal-regulated Kinase Kinase/Mitogen-activated Protein Kinase Inhibitors Interact Synergistically with STI571 to Induce Apoptosis in Bcr/Abl-expressing Human Leukemia Cells.
C. Yu, G. Krystal, L. Varticovksi, R. McKinstry, M. Rahmani, P. Dent, and S. Grant (2002)
Cancer Res. 62, 188-199
   Abstract »    Full Text »    PDF »
Primitive, quiescent, Philadelphia-positive stem cells from patients with chronic myeloid leukemia are insensitive to STI571 in vitro.
S. M. Graham, H. G. Jorgensen, E. Allan, C. Pearson, M. J. Alcorn, L. Richmond, and T. L. Holyoake (2002)
Blood 99, 319-325
   Abstract »    Full Text »    PDF »
How do tumors make ends meet?.
C. Lengauer (2001)
PNAS 98, 12331-12333
   Full Text »    PDF »
Down-regulation of interleukin-3/granulocyte-macrophage colony-stimulating factor receptor {beta}-chain in BCR-ABL+ human leukemic cells: association with loss of cytokine-mediated Stat-5 activation and protection from apoptosis after BCR-ABL inhibition.
N. J. Donato, J. Y. Wu, L. Zhang, H. Kantarjian, and M. Talpaz (2001)
Blood 97, 2846-2853
   Abstract »    Full Text »    PDF »
Bcr/Abl activates transcription of the Bcl-X gene through STAT5.
F. Gesbert and J. D. Griffin (2000)
Blood 96, 2269-2276
   Abstract »    Full Text »    PDF »
Novel oxime derivatives of radicicol induce erythroid differentiation associated with preferential G1 phase accumulation against chronic myelogenous leukemia cells through destabilization of Bcr-Abl with Hsp90 complex.
Y. Shiotsu, L. M. Neckers, I. Wortman, W. G. An, T. W. Schulte, S. Soga, C. Murakata, T. Tamaoki, and S. Akinaga (2000)
Blood 96, 2284-2291
   Abstract »    Full Text »    PDF »
Clinical Use of Tyrosine Kinase Inhibitors: Therapy for Chronic Myelogenous Leukemia and Other Cancers.
N. J. Donato and M. Talpaz (2000)
Clin. Cancer Res. 6, 2965-2966
   Full Text »
The Heat Shock Protein 90 Antagonist Geldanamycin Alters Chaperone Association with p210bcr-abl and v-src Proteins before Their Degradation by the Proteasome.
W. G. An, T. W. Schulte, and L. M. Neckers (2000)
Cell Growth Differ. 11, 355-360
   Abstract »    Full Text »
Mechanism of resistance to the ABL tyrosine kinase inhibitor STI571 in BCR/ABL-transformed hematopoietic cell lines.
E. Weisberg and J. D. Griffin (2000)
Blood 95, 3498-3505
   Abstract »    Full Text »    PDF »
Vaccination of patients with chronic myelogenous leukemia with bcr-abl oncogene breakpoint fusion peptides generates specific immune responses.
J. Pinilla-Ibarz, K. Cathcart, T. Korontsvit, S. Soignet, M. Bocchia, J. Caggiano, L. Lai, J. Jimenez, J. Kolitz, and D. A. Scheinberg (2000)
Blood 95, 1781-1787
   Abstract »    Full Text »    PDF »
The c-Fes Protein-Tyrosine Kinase Suppresses Cytokine-independent Outgrowth of Myeloid Leukemia Cells Induced by Bcr-Abl.
J. M. Lionberger and T. E. Smithgall (2000)
Cancer Res. 60, 1097-1103
   Abstract »    Full Text »
Expression Cloning of Protein Targets for 3-Phosphorylated Phosphoinositides.
V. R. Rao, M. N. Corradetti, J. Chen, J. Peng, J. Yuan, G. D. Prestwich, and J. S. Brugge (1999)
J. Biol. Chem. 274, 37893-37900
   Abstract »    Full Text »    PDF »
BCR/ABL Directly Inhibits Expression of SHIP, an SH2-Containing Polyinositol-5-Phosphatase Involved in the Regulation of Hematopoiesis.
M. Sattler, S. Verma, C. H. Byrne, G. Shrikhande, T. Winkler, P. A. Algate, L. R. Rohrschneider, and J. D. Griffin (1999)
Mol. Cell. Biol. 19, 7473-7480
   Abstract »    Full Text »    PDF »
Autocrine production and action of IL-3 and granulocyte colony-stimulating factor in chronic myeloid leukemia.
X. Jiang, A. Lopez, T. Holyoake, A. Eaves, and C. Eaves (1999)
PNAS 96, 12804-12809
   Abstract »    Full Text »    PDF »
Antisense Inhibition of Hyaluronan Synthase-2 in Human Articular Chondrocytes Inhibits Proteoglycan Retention and Matrix Assembly.
Y. Nishida, C. B. Knudson, J. J. Nietfeld, A. Margulis, and W. Knudson (1999)
J. Biol. Chem. 274, 21893-21899
   Abstract »    Full Text »    PDF »
Characterization of a Novel Receptor That Maps Near the Natural Killer Gene Complex: Demonstration of Carbohydrate Binding and Expression in Hematopoietic Cells.
M. J. Fernandes, A. A. Finnegan, L. D. Siracusa, C. Brenner, N. N. Iscove, and B. Calabretta (1999)
Cancer Res. 59, 2709-2717
   Abstract »    Full Text »    PDF »
The Lck Binding Domain of Herpesvirus Saimiri Tip-484 Constitutively Activates Lck and STAT3 in T Cells.
T. C. Lund, P. C. Prator, M. M. Medveczky, and P. G. Medveczky (1999)
J. Virol. 73, 1689-1694
   Abstract »    Full Text »
Mutations in the Hydrophobic Surface of an Amphipathic Groove of 14-3-3zeta Disrupt Its Interaction with Raf-1 Kinase.
H. Wang, L. Zhang, R. Liddington, and H. Fu (1998)
J. Biol. Chem. 273, 16297-16304
   Abstract »    Full Text »    PDF »
BCR-ABL Delays Apoptosis Upstream of Procaspase-3 Activation.
L. Dubrez, B. Eymin, O. Sordet, N. Droin, A. G. Turhan, and E. Solary (1998)
Blood 91, 2415-2422
   Abstract »    Full Text »    PDF »
Suppression of Cell Proliferation and the Expression of a bcr-abl Fusion Gene and Apoptotic Cell Death in a New Human Chronic Myelogenous Leukemia Cell Line, KT-1, by Interferon-alpha.
K. Yanagisawa, H. Yamauchi, M. Kaneko, H. Kohno, H. Hasegawa, and S. Fujita (1998)
Blood 91, 641-648
   Abstract »    Full Text »    PDF »
The Src Family Kinase Hck Interacts with Bcr-Abl by a Kinase-independent Mechanism and Phosphorylates the Grb2-binding Site of Bcr.
M. Warmuth, M. Bergmann, A. Priess, K. Hauslmann, B. Emmerich, and M. Hallek (1997)
J. Biol. Chem. 272, 33260-33270
   Abstract »    Full Text »    PDF »
BCR-ABL Transcripts in Bone Marrow Aspirates of Philadelphia-Negative Essential Thrombocythemia Patients: Clinical Presentation.
D. Blickstein, A. Aviram, J. Luboshitz, M. Prokocimer, P. Stark, O. Bairey, J. Sulkes, and M. Shaklai (1997)
Blood 90, 2768-2771
   Abstract »    Full Text »    PDF »
HLA-DR1-Restricted bcr-abl (b3a2)-Specific CD4+ T Lymphocytes Respond to Dendritic Cells Pulsed With b3a2 Peptide and Antigen-Presenting Cells Exposed to b3a2 Containing Cell Lysates.
S.I. Mannering, J.L. McKenzie, D.B. Fearnley, and D.N.J. Hart (1997)
Blood 90, 290-297
   Abstract »    Full Text »    PDF »
Interactions of CBL with BCR-ABL and CRKL in BCR-ABL-transformed Myeloid Cells.
A. Bhat, K. Kolibaba, T. Oda, S. Ohno-Jones, C. Heaney, and B. J. Druker (1997)
J. Biol. Chem. 272, 16170-16175
   Abstract »    Full Text »    PDF »
Distribution of ABL and BCR Genes in Cell Nuclei of Normal and Irradiated Lymphocytes.
S. Kozubek, L. Ryznar, M. Kozubek, R.D. Govorun, E.A. Krasavin, and G. Horneck (1997)
Blood 89, 4537-4545
   Abstract »    Full Text »    PDF »
Direct Binding of CRKL to BCR-ABL Is Not Required for BCR-ABL Transformation.
C. Heaney, K. Kolibaba, A. Bhat, T. Oda, S. Ohno, S. Fanning, and B. J. Druker (1997)
Blood 89, 297-306
   Abstract »    Full Text »    PDF »
Cell cycle control and cancer.
L. Hartwell and M. Kastan (1994)
Science 266, 1821-1828
   Abstract »    PDF »
Association of the protein kinases c-Bcr and Bcr-Abl with proteins of the 14-3-3 family.
G. Reuther, H Fu, L. Cripe, R. Collier, and A. Pendergast (1994)
Science 266, 129-133
   Abstract »    PDF »
Detection of bcr-abl fusion in chronic myelogeneous leukemia by in situ hybridization.
D. Tkachuk, C. Westbrook, M Andreeff, T. Donlon, M. Cleary, K Suryanarayan, M Homge, A Redner, J Gray, and D Pinkel (1990)
Science 250, 559-562
   Abstract »    PDF »
Molecular analysis of acute promyelocytic leukemia breakpoint cluster region on chromosome 17.
J Borrow, A. Goddard, D Sheer, and E Solomon (1990)
Science 249, 1577-1580
   Abstract »    PDF »
Tyrosine kinase activity and transformation potency of bcr-abl oncogene products.
T. Lugo, A. Pendergast, A. Muller, and O. Witte (1990)
Science 247, 1079-1082
   Abstract »    PDF »
Expression of a distinctive BCR-ABL oncogene in Ph1-positive acute lymphocytic leukemia (ALL).
S. Clark, J McLaughlin, M Timmons, A. Pendergast, Y Ben-Neriah, L. Dow, W Crist, G Rovera, S. Smith, and O. Witte (1988)
Science 239, 775-777
   Abstract »    PDF »
The CML-specific P210 bcr/abl protein, unlike v-abl, does not transform NIH/3T3 fibroblasts.
G. Daley, J McLaughlin, O. Witte, and D Baltimore (1987)
Science 237, 532-535
   Abstract »    PDF »
The molecular genetics of cancer.
J. Bishop (1987)
Science 235, 305-311
   Abstract »    PDF »
Unique forms of the abl tyrosine kinase distinguish Ph1-positive CML from Ph1-positive ALL.
S. Clark, J McLaughlin, W. Crist, R Champlin, and O. Witte (1987)
Science 235, 85-88
   Abstract »    PDF »
Transformation of Myeloid Leukemia Cells to Cytokine Independence by Bcr-Abl Is Suppressed by Kinase-defective Hck.
J. M. Lionberger, M. B. Wilson, and T. E. Smithgall (2000)
J. Biol. Chem. 275, 18581-18585
   Abstract »    Full Text »    PDF »
Inhibition of Cell Migration by Abl Family Tyrosine Kinases through Uncoupling of Crk-CAS Complexes.
K. H. Kain and R. L. Klemke (2001)
J. Biol. Chem. 276, 16185-16192
   Abstract »    Full Text »    PDF »


To Advertise     Find Products

Science. ISSN 0036-8075 (print), 1095-9203 (online)